Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Percutaneous Pulmonary Artery Denervation (PADN) for the Treatment of Pulmonary Hypertension After Transcatheter Mitral Valve Edge-to-Edge Repair (M-TEER): A Prospective Cohort Study

this study aims to investigate the efficacy and safety of PADN therapy compared with standard medical therapy in patients diagnosed with pulmonary hypertension after M-TEER, thereby providing evidence for clinical treatment decision-making

Participants needed: 60
Trial details
Phase: Early Phase 1Age: 18-80Biological sex: AllType: InterventionalSponsor: Xiamen Cardiovascular Hospital, Xiamen UniversityUpdated: Jun 23, 2026Locations: 1
Eligibility criteria

Age ≥18 years and ≤80 years; [+4]

Cardiac index (CI) < 1.5 L/min/m²; [+15]

Status: Recruiting

Structural Heart Surgery Assist System for Transcatheter Mitral Valve Edge-to-Edge Repair (TEER).

This trial aims to evaluate the safety and efficacy of the Structural Heart Surgery Assist System in assisting TEER for patients with moderate-to-severe or greater degenerative or functional mitral regurgitation (MR ≥3+). A prospective, multicenter, stratified randomized controlled design with non-inferiority comparison will be used. The experimental group will utilize the Structural Heart Surgery Assist System, while the control group will undergo manual TEER (e.g., MitraClip G4).

Participants needed: 112
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Xiamen Cardiovascular Hospital, Xiamen UniversityUpdated: Jul 9, 2025Locations: 1
Eligibility criteria

Age ≥18 years, regardless of gender. [+5]

Rheumatic mitral valve disease. [+19]

Status: Not yet recruiting

Optimized Strategies for Malperfusion Syndrome

An investigator-initiated, randomized, multicenter, two-arm, open-label study of consecutive patients presenting with acute type A aortic dissection (ATAAD) and malperfusion syndrome (MPS). Objectives: The present study aimed to investigate the difference in all-cause mortality after optimized treatment strategies (OTS) versus traditional treatment strategies (TTS) for ATAAD patients with MPS. Background: The mortality of ATAAD with MPS is high. However, the management strategies of MPS patients still not to be confirmed. Compare with TTS, OTS as a strategy for ATAAD patients with MPS might have be beneficial results.

Participants needed: 236
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Xiamen Cardiovascular Hospital, Xiamen UniversityUpdated: Aug 1, 2024Locations: 1
Eligibility criteria

Provision of informed consent prior to any study specific procedures; [+4]

Age <18 yr and >80 yr; [+8]